Dynasty Wealth Management LLC Purchases Shares of 12,012 AstraZeneca PLC (NASDAQ:AZN)

Dynasty Wealth Management LLC purchased a new position in shares of AstraZeneca PLC (NASDAQ:AZN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 12,012 shares of the company’s stock, valued at approximately $787,000.

A number of other institutional investors have also modified their holdings of AZN. Capital Performance Advisors LLP acquired a new position in shares of AstraZeneca in the 3rd quarter valued at $28,000. Ashton Thomas Securities LLC purchased a new position in AstraZeneca in the third quarter valued at $45,000. Albion Financial Group UT raised its position in shares of AstraZeneca by 68.9% in the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after acquiring an additional 248 shares during the period. Hollencrest Capital Management boosted its stake in shares of AstraZeneca by 38.4% during the 3rd quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock worth $54,000 after acquiring an additional 192 shares in the last quarter. Finally, Versant Capital Management Inc grew its position in shares of AstraZeneca by 2,618.5% during the 4th quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock valued at $48,000 after acquiring an additional 707 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

AZN has been the subject of a number of analyst reports. UBS Group raised AstraZeneca from a “neutral” rating to a “buy” rating in a report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Finally, Morgan Stanley began coverage on shares of AstraZeneca in a research note on Wednesday, February 12th. They issued an “overweight” rating on the stock. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Price Performance

Shares of AstraZeneca stock opened at $76.21 on Friday. The stock has a market capitalization of $236.34 billion, a P/E ratio of 33.72, a PEG ratio of 1.42 and a beta of 0.46. The business has a 50 day simple moving average of $69.75 and a two-hundred day simple moving average of $73.07. AstraZeneca PLC has a 12 month low of $62.75 and a 12 month high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. As a group, analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Monday, March 24th. Investors of record on Friday, February 21st will be given a dividend of $1.03 per share. The ex-dividend date of this dividend is Friday, February 21st. This is a positive change from AstraZeneca’s previous semi-annual dividend of $0.49. This represents a yield of 2%. AstraZeneca’s payout ratio is presently 91.15%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.